1d ago

HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve

Why does accurate HER2 testing matter more than ever for patients with breast cancer? Dr. Neil Iyengar and Dr. Sunil Badve discuss the evolving understanding of HER2-low and HER2-ultralow breast cancer and how advances in pathology and clinical evidence are expanding the population of patients who may be candidates for trastuzumab deruxtecan (T-DXd). Drawing on findings from DESTINY-Breast04 and DESTINY-Breast06, they explore how HER2 assessment has moved beyond the traditional amplified versus non-amplified framework, why accurately identifying low levels of HER2 expression matters, and how clinicians and pathologists can work together to reduce the risk of missing potential treatment opportunities. Topics discussed: How HER2 testing has evolved from identifying amplification to detecting low levels of protein expressionDefining HER2-low, HER2-ultralow, and HER2-null diseaseLimitations of current HER2 assays at very low levels of expressionPre-analytic and analytic factors that can affect HER2 testingKey considerations when interpreting HER2 IHC resultsHow DESTINY-Breast04 established T-DXd as a treatment option in HER2-low metastatic breast cancerHow DESTINY-Breast06 expanded the discussion to HER2-ultralow disease and earlier use of T-DXdWhy repeat biopsy and reassessment of HER2 expression can matterWhen archival tissue or a pathology second opinion may be usefulTumor heterogeneity and changes in HER2 expression over time and across metastatic sitesHER2-low expression in hormone receptor-positive and triple-negative breast cancerManaging T-DXd-associated nausea, fatigue, ILD, and cardiac considerationsImproving concordance in HER2 assessment through training and standardized testingThe emerging role of AI and quantitative tools in evaluating HER2 expressionWhat DESTINY-Breast15 could mean for HER2 testing and patients with HER2 IHC 0 disease ▶️ Watch the full CHM Conversation for expert perspectives on HER2 testing, evolving pathology standards, and identifying patients who may benefit from T-DXd. #NeilIyengar #SunilBadve #CHMConversations #HER2Low #HER2Ultralow #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast04 #DESTINYBreast06 #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: Spotify - https://spotf.fi/chm-podcast Amazon Music - https://amazn.so/chm-podcast Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 Castbox - https://castbox.fm/vh/6735434 Goodpods - https://goodpods.com/profile/chm-111066 iHeartRadio - https://iheart.com/podcast/291542082 Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: Peer to peer interviews, panels & round-tables Curated live events & conferences Professional in-depth content & research updates Interactive learning modules & webinars Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Oct 7

Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino

How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care? In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions. They explore what the newly approved combination of imlunestrant plus abemaciclib means for patients with ESR1 mutations, how ctDNA and molecular profiling guide treatment selection, and why sequencing next-generation endocrine therapies remains an open question as new options emerge. Topics discussed: EMBER-3 and imlunestrant plus abemaciclibTreatment options for ESR1-mutated diseaseSingle-agent vs combination endocrine therapyctDNA and molecular profilingBiomarker-driven treatment selectionBalancing efficacy and tolerabilitySERENA-6 and molecular progressionSequencing next-generation endocrine therapiesOral SERDs in the adjuvant and first-line settingsEmerging doublet and triplet strategies ▶️ Watch this Special CHM Conversation for expert perspectives on navigating the evolving second-line treatment landscape in ER-positive, HER2-negative metastatic breast cancer. #SethWander #PaoloTarantino #CHMConversations #ESR1 #EMBER3 #EndocrineTherapy #OralSERD #MetastaticBreastCancer #BreastCancer #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: Peer to peer interviews, panels & round-tables Curated live events & conferences Professional in-depth content & research updates Interactive learning modules & webinars Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Oct 6

ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton

How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer? Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing. They explore when and how to test for ESR1 mutations, including the role of liquid biopsy and serial testing as resistance emerges. The conversation also examines the differences between a PROTAC and oral SERDs, the clinical data supporting vepdegestrant, and how emerging combination strategies could further reshape endocrine therapy. Topics discussed: • Why ESR1 mutations matter in HR-positive/HER2-negative metastatic breast cancer • When to test and retest for ESR1 mutations • Tissue NGS vs liquid biopsy for detecting ESR1 mutations • ESR1 as both a resistance mechanism and a predictive biomarker • Current treatment options for ESR1-mutated disease • How PROTACs differ from oral SERDs • VERITAC-2 and the clinical data supporting vepdegestrant • Understanding VERITAC-2, EMERALD, and EMBER-3 • Tolerability, GI toxicity, fatigue, and QTc monitoring with vepdegestrant • Selecting among endocrine monotherapy options • Retesting ESR1 after progression on an oral SERD • Sequencing a PROTAC after prior oral SERD therapy • Imlunestrant plus abemaciclib and emerging combination strategies • SERENA-6 and switching therapy at molecular progression • Molecular progression vs radiologic progression • The future role of PROTAC and CDK4/6 inhibitor combinations • Why endocrine monotherapy still has an important role • Preserving endocrine therapy before transitioning to antibody-drug conjugates • Reconsidering endocrine therapy after treatment with an ADC • The growing importance of genomic profiling and personalized treatment sequencing ▶️ Watch the full CHM Conversation for expert perspectives on ESR1 testing, endocrine resistance, treatment selection, and the evolving role of oral SERDs and PROTACs in metastatic breast cancer. #JasonMouabbi #ErikaHamilton #CHMConversations #BreastCancer #MetastaticBreastCancer #ESR1 #HRPositiveBreastCancer #HER2Negative #Vepdegestrant #OralSERD #PROTAC #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Oct 6

T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander

How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer? Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of trastuzumab deruxtecan (T-DXd) across metastatic and early-stage HER2-positive breast cancer. From the first-line DESTINY-Breast09 data to the neoadjuvant DESTINY-Breast11 and adjuvant DESTINY-Breast05 data, they explore the new opportunities and clinical questions around treatment selection, maintenance, toxicity management, and personalization. Topics discussed: • How DESTINY-Breast09 is changing first-line treatment for metastatic HER2-positive breast cancer • T-DXd plus pertuzumab compared with the long-standing CLEOPATRA approach • Why earlier use of T-DXd may improve disease control • HER2 heterogeneity and the potential impact of T-DXd on CNS progression • Selecting patients for first-line T-DXd plus pertuzumab • Complete response, deep partial response, and time to maximal response • When and how to consider transitioning from T-DXd to maintenance therapy • PATINA and the role of palbociclib in ER-positive/HER2-positive maintenance • HER2CLIMB-05 and adding tucatinib to trastuzumab and pertuzumab maintenance • Personalizing maintenance according to hormone receptor status • Treatment considerations after progression on first-line T-DXd • PIK3CA mutations and outcomes with THP vs T-DXd plus pertuzumab • Managing T-DXd-associated fatigue, nausea, cytopenias, alopecia, and ILD/pneumonitis • Practical approaches to ILD screening, monitoring, treatment, and rechallenge • DESTINY-Breast11 and incorporating T-DXd into neoadjuvant treatment • DESTINY-Breast05 and T-DXd for residual disease after neoadjuvant therapy • Treatment decisions when residual disease remains after neoadjuvant T-DXd • The evolving role of CT monitoring in early-stage T-DXd treatment • Future personalization using MRD, ctDNA, targeted therapies, and treatment escalation or de-escalation ▶️ Watch the full CHM Conversation for expert perspectives on integrating T-DXd across the evolving HER2-positive breast cancer treatment landscape. #PaoloTarantino #SethWander #CHMConversations #HER2PositiveBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #DESTINYBreast11 #DESTINYBreast05 #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Oct 5

T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang

How is T-DXd changing the treatment landscape for HER2-positive breast cancer? Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan (T-DXd) across HER2-positive breast cancer, from first-line metastatic disease to neoadjuvant and adjuvant treatment. They examine data from DESTINY-Breast09, DESTINY-Breast05, and DESTINY-Breast11, along with emerging maintenance strategies from PATINA and HER2CLIMB-05. The conversation also explores how these findings are influencing treatment selection, duration, sequencing, toxicity management, and individualized patient care. Topics discussed: How DESTINY-Breast09 is changing first-line treatment for metastatic HER2-positive breast cancerT-DXd plus pertuzumab versus the traditional THP approachComplete response, deep partial response, and how long to continue T-DXd plus pertuzumabWhen THP followed by maintenance therapy may still be consideredManaging T-DXd-associated nausea, ILD/pneumonitis, and fatigueScreening, monitoring, and rechallenge considerations for ILDPATINA and HER2CLIMB-05 maintenance strategiesHow first-line T-DXd may affect subsequent treatment sequencingDESTINY-Breast05 and the role of adjuvant T-DXd in patients with residual diseaseDESTINY-Breast11 and incorporating T-DXd into neoadjuvant therapySelecting patients for neoadjuvant versus adjuvant T-DXdTreatment considerations when residual disease remains after neoadjuvant T-DXdThe potential impact of T-DXd on CNS recurrence and future HER2-positive treatment strategies ▶️ Watch the full CHM Conversation for expert perspectives on translating evolving HER2-positive breast cancer evidence into clinical practice. #RutaRao #IreneKang #CHMConversations #HER2PositiveBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #DESTINYBreast05 #DESTINYBreast11 #CommunityHealthMedia– Thanks for watching! Our podcasts are also available on: Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11oCommunity Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Oct 2

T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar

How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer? Drs. Jason Mouabbi and Neil Iyengar discuss the evolving role of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line metastatic HER2-positive breast cancer and how the DESTINY-Breast09 findings are influencing clinical decision-making. They examine how this approach compares with the long-standing CLEOPATRA regimen, why depth and duration of response matter, and how clinicians can balance efficacy, tolerability, maintenance strategies, and future treatment sequencing when individualizing care. Topics discussed: The HER2-positive metastatic breast cancer landscape before DESTINY-Breast09How DESTINY-Breast09 compared T-DXd plus pertuzumab with the CLEOPATRA regimenProgression-free survival and the clinical implications of the DB-09 resultsWhy using the most active therapies earlier may influence treatment outcomesComplete response and the emerging concept of deep partial responseHow treatment duration may affect depth of response with T-DXd plus pertuzumabTreatment considerations for patients with PIK3CA-mutated HER2-positive diseaseManaging T-DXd-associated nausea and the role of proactive antiemetic therapyILD monitoring, including kidney function, and rechallenge following grade 1 ILDCardiac monitoring during HER2-directed therapyWhere PATINA and HER2CLIMB-05 maintenance fitTreatment options after progression on first-line T-DXd plus pertuzumabThe potential role of rebiopsy and changes in HER2 expression after T-DXdHow prior neoadjuvant or adjuvant T-DXd may influence treatment at metastatic recurrence ▶️ Watch the full CHM Conversation for expert perspectives on applying evolving HER2-positive breast cancer evidence to clinical practice. #JasonMouabbi #NeilIyengar #CHMConversations #HER2PositiveBreastCancer #MetastaticBreastCancer #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast09 #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Sep 29

Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs

With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options? Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient preferences can guide treatment selection. Topics discussed: Fixed-duration vs. continuous first-line therapy Choosing among BTK inhibitor-based strategies Acalabrutinib + venetoclax and venetoclax + obinutuzumab Treatment considerations for TP53 mutation and del(17p) The emerging investigational role of pirtobrutinib in frontline CLL Key testing to inform first-line CLL treatment decisions Sequencing therapy and the role of BTK inhibitors after frontline venetoclax-based therapy or chemoimmunotherapy ▶️ Watch the full CHM Conversation and subscribe for more expert discussions translating evolving evidence into clinical practice. #CHMConversations #KerryRogers #WilliamWierda #CatherineCoombs #CLL #ChronicLymphocyticLeukemia #BTKInhibitors #Venetoclax #Hematology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Sep 1

Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation. In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer. They explore which patients may benefit most from a T-DXd-based approach, how prior T-DXd exposure in early-stage disease could influence treatment at metastatic recurrence, and where THP may still have a role. The conversation also examines practical considerations around toxicity management, maintenance strategies in HER2+ disease, sequencing, and individualized treatment selection. Topics discussed: How CLEOPATRA and THP established the first-line standard DESTINY-Breast09 and T-DXd plus pertuzumab Treatment considerations for high-risk and HR+/HER2+ disease Brain metastases and high visceral disease burden How prior neoadjuvant or adjuvant T-DXd may influence treatment Managing nausea, fatigue, and ILD with T-DXd Dose modifications and maintaining quality of life with T-DXd PATINA and HER2CLIMB-05 maintenance approaches Treatment sequencing after first-line T-DXd plus pertuzumab ▶️ Watch the full conversation and subscribe to Community Health Media for more expert perspectives on the latest research and evolving approaches in cancer care. #CHMConversations #SonyaReid #ShrutiSingh #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #TrastuzumabDeruxtecan #BreastCancer #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast... • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Community Health Media

HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve

Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino

ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton

T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander

T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang

T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar

Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

About

Information

You Might Also Like

Community Health Media

Episodes

HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve

Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino

ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton

T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander

T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang

T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar

Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs

Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

About

Information

You Might Also Like